Compare Organon & Co. Common Stock (OGN) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Rush Street Interactive Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Rush Street Interactive Inc trades at $18.31 (market cap $2.14B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Rush Street Interactive Inc for 13 Days on average.
| OGN | RSI | |
|---|---|---|
Market Cap | $3.61B | $2.14B |
Volume | 1,808,049 | 1,828,735 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $34.52 |
52-Week Low | $5.70 | $15.89 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $11.03B | $1.80B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Rush Street Interactive (RSI) trades at $19.07, up 1.92% with mixed technical signals showing bearish moving averages but neutral RSI levels. The company reported strong Q2 2026 earnings with record revenue and adjusted EBITDA, beating expectations with $0.15 EPS versus $0.1499 forecast. Analyst consensus remains strongly bullish with 76.9% buy ratings and a $33.75 price target, representing 77% upside potential from current levels.
While technical indicators show near-term bearish pressure, strong fundamentals with 20.7% ROE and positive earnings momentum support long-term growth prospects. Key risks include competitive pressures in online gambling and market volatility, but institutional buying from BlackRock and Dimensional Fund Advisors signals confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
